Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY agreed to acquire 2seventy bio, Inc TSVT. Meanwhile, other pipeline and ...

Philadelphia-based Endo sold its international pharma unit to Knight Therapeutics this week for up to $99 million, while Ireland-headquartered Mallinckrodt sold Therakos, a specialist in ...

Morgan Stanley analyst Ravi Shanker maintained a Hold rating on JetBlue Airways (JBLU – Research Report) today and set a price target of $8.00.

Mallinckrodt and Endo were both involved in the sale of opioid painkillers and faced litigation claiming that they played a ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...